ClinicalTrials.gg
CompletedNCT06325657MORISOTUpdated Jul 2, 2026Results posted

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

A Phase 3 interventional study of RSVpreF vaccine and Placebp in Respiratory Syncytial Virus, sponsored by Pfizer. Completed at 14 sites in South Africa. Open to participants aged 0 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
681
Allocation
Randomized
Ages
0 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Respiratory Tract Infections by Pfizer — 2 open to participants now, 3 under way, 2 of them phase 3. Respiratory Tract Infections · Pfizer.

Enrollment
7th of 18
681 · median 309
Started
2024
with 3 others
Phase 3
7 of 23
2 open now
Registered
17th of 23
by date

Among the 23 studies in Respiratory Tract Infections by Pfizer, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, and was the 17th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 23 studies in Respiratory Tract Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 0 Years to 49 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Respiratory Tract Infections by Pfizer, or all of them as a file.
02

Study summary

The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV. These infants may have higher chances of getting sick or dying due to RSV infection. Respiratory Syncytial Virus (RSV) is a common type of virus (germ) that can cause severe illness (airway diseases), where medical help is needed. Vaccines help your body make antibodies which help fight against diseases. The antibodies are substances your body uses to fight off an infection. The antibodies can be passed to the infant through the placenta of the mother.

The study will look at the safety, tolerability, and immune activity in mothers and their infants.

This study is seeking pregnant women who are:

  • Less than or equal to 49 years old and have HIV (Human immunodeficiency virus -
  • Receiving standard medical care during the pregnancy
  • Do not have syphilis (bacterial sexually transmitted disease), Hepatitis B Virus ((HBV) liver infection), Tuberculosis ((TB) bacterial lung infection).
  • Have been on stable (anti-retroviral) HIV treatment for more than or equal to 90 days.
  • agree to be present for all study visits, procedures, and blood draws.

Participants will either receive:

  • RSVpreF vaccine
  • A placebo. A placebo does not have any medicine it but looks just like the study vaccine.

Pregnant participants will be involved in the study from:

  • consent during their current pregnancy, and
  • for 6 months after delivery of their baby (around 10 months in total). Pregnant participants will have at least 5 planned visits in this study. Infant participants: All eligible babies born to enrolled mothers will be followed up from birth for up to 6 months. Infant participants will have at least 3 study visits, with some site visits allowed to happen via home visits or over the telephone.
03

Conditions studied

  • Respiratory Syncytial Virus

Keywords

  • Respiratory Tract Infection
  • HIV
  • Maternal
  • Vaccine
04

Who can participate

Ages eligible
0 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria - Maternal Participants

  • Women ≤49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated singleton pregnancy who are at no known increased risk for complications.
  • Confirmed stable disease.
  • Current and stable use of antiretroviral therapy(ART) for at least 90 days prior to enrolment.
  • Had a fetal anomaly ultrasound examination performed at ≥18 weeks of pregnancy with no significant fetal abnormalities observed.
  • Intention to deliver at a hospital or birthing facility where study procedures can be obtained.
  • Participant is willing to give for the participant's infant to participate in the study.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol.

Key Inclusion Criteria - Infant Participants

  • Evidence of a signed and dated ICD, signed by the parent(s)/legal guardian(s).
  • Parent(s)/legal guardian(s) willing and able to comply with scheduled visits, plan, laboratory tests, and other study procedures

Key Exclusion Criteria - Maternal Participants

  • Prepregnancy (BMI) of >40 kg/m2 . If prepregnancy BMI is not available, the BMI at the time of the first obstetric visit during the current pregnancy may be used.
  • Participant with opportunistic infections or .
  • History of active chronic viral hepatitis with biochemical evidence of (AST) or alanine aminotransferase (ALT) values >5 times the within 6 months before enrollment.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.
  • Current pregnancy resulting from in vitro fertilization. Participants known to have used clomiphene citrate and/or letrozole with or without intrauterine insemination (IUI) are permitted.
  • Current pregnancy complications or abnormalities at the time of consent that will increase the risk associated with the participation in and completion of the study, including but not l limited to the following:
  • Preeclampsia, eclampsia, or uncontrolled gestational hypertension.
  • Placental abnormality.
  • Polyhydramnios or oligohydramnios.
  • Significant bleeding or blood clotting disorder.
  • Endocrine disorders, including untreated hyperthyroidism or untreated hypothyroidism. This also includes disorders of glucose intolerance (eg, diabetes mellitus type 1 or 2) antedating pregnancy or occurring during pregnancy if uncontrolled at the time of consent.
  • Any signs of premature labor with the current pregnancy or having ongoing intervention (medical/surgical) in the current pregnancy to prevent preterm birth.
  • Prior pregnancy complications or abnormalities at the time of consent, based on the investigator's judgment, that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:
  • Prior preterm delivery at ≤34 weeks' gestation
  • Prior stillbirth or neonatal death
  • Previous infant with a known genetic disorder or significant congenital anomaly
  • Non-HIV-associated congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other illness requiring chronic treatment with known medications.
  • Antituberculosis treatment use currently or at any time during this current pregnancy.

Key Exclusion Criteria - Infant Participants

  • Infant who is a direct descendant (eg, child or grandchild) of the investigator site staff or sponsor and sponsor delegate employees directly involved in the conduct of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
681 participants (actual)

Study arms

  • Experimental
    RSVpreF vaccine

    RSV vaccine (RSVpreF)

    Biological: RSVpreF vaccine

  • Placebo comparator
    Placebo

    Placebo

    Biological: Placebp

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination

    Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.

    Time frame: From Day 1 to Day 7 after vaccination

  2. Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination

    Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \[H\]), moderate (\>2 times in 24 H), severe (required intravenous \[IV\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.

    Time frame: From Day 1 to Day 7 after vaccination

  3. Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  4. Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)

    AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).

    Time frame: From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)

  5. Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.

    Time frame: From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)

  6. Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age

    AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \[\<=\] 1000 g) were reported as serious AESIs.

    Time frame: From birth up to 6 months of age

  7. Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age

    Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.

    Time frame: Within 1 Month after birth

  8. Number of Infant Participants With Congenital Malformations/Anomalies at Birth

    Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.

    Time frame: At birth

  9. Number of Infant Participants With Other Neonatal Problems at Birth

    Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.

    Time frame: At birth

  10. Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth

    APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

    Time frame: 1 minute after birth

  11. Number of Infant Participants According to APGAR Score at 5 Minutes After Birth

    APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

    Time frame: 5 minutes after birth

  12. Number of Infant Participants According to APGAR Score at 10 Minutes After Birth

    APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

    Time frame: 10 minutes after birth

  13. Number of Infant Participants According to Gestational Age (GA) at Birth

    GA at birth was collected as:\>=24 to \<28 weeks, \>=28 to \<34 weeks, \>=34 to \<37 weeks, \>=37 to \<42 weeks, and \>=42 weeks.

    Time frame: At birth

  14. Number of Infant Participants Requiring Hospitalization at Birth

    Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.

    Time frame: From birth until discharge from hospitalization (up to a maximum of 72 hours)

  15. Percentage of Infant Participants With AEs From Birth to 1 Month of Age

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From birth to 1 month of age

  16. Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.

    Time frame: From birth to 6 months of age

  17. Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.

    Time frame: From birth to 6 months of age

Secondary outcomes

  1. Geometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants

    GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.

    Time frame: Before vaccination on Day 1 and at delivery

  2. Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants

    GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.

    Time frame: Before vaccination on Day 1 to delivery

07

Results

Posted Jul 2, 2026

Participant flow

Participant flow — Overall Study
MilestoneMaternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: Placebo
Started172171171167
Safety population172170171166
Completed167163165158
Not completed5869
Withdrew: Death1213
Withdrew: Lost to follow-up3342
Withdrew: Protocol deviation0100
Withdrew: Withdrawal by subject1200
Withdrew: Withdrawal by parent/guardian0012
Withdrew: Other0002

Outcome measures

PrimaryPercentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination

Local reactions included redness, swelling, and pain at injection site and were recorded in electronic diary (e-diary). Redness and swelling were measured by the maternal participant and recorded in measuring device units (mdu) in the e-diary (range: 1 to 21). 1 mdu = 0.5 centimetre (cm). Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and grade 4 (emergency room visit or hospitalization for severe pain at the injection site). Grade 4 reactions were classified by the investigator or medically qualified designee.

Time frame:
From Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With Prespecified Local Reactions Within 7 Days After Vaccination
Percentage of participantsMaternal Participants: RSVpreFMaternal Participants: Placebo
Redness: Any1.8 (0.4 to 5.3)1.8 (0.4 to 5.2)
Redness: Mild0 (0.0 to 2.2)1.2 (0.1 to 4.3)
Redness: Moderate1.8 (0.4 to 5.3)0.6 (0.0 to 3.3)
Redness: Severe0 (0.0 to 2.2)0 (0.0 to 2.2)
Swelling: Any2.5 (0.7 to 6.2)2.4 (0.7 to 6.1)
Swelling: Mild0.6 (0.0 to 3.4)1.2 (0.1 to 4.3)
Swelling: Moderate1.8 (0.4 to 5.3)0.6 (0.0 to 3.3)
Swelling: Severe0 (0.0 to 2.2)0.6 (0.0 to 3.3)
Pain at injection site: Any27.0 (20.3 to 34.5)17.5 (12.0 to 24.1)
Pain at injection site: Mild20.9 (14.9 to 27.9)11.4 (7.0 to 17.3)
Pain at injection site: Moderate6.1 (3.0 to 11.0)5.4 (2.5 to 10.0)
Pain at injection site: Severe0 (0.0 to 2.2)0.6 (0.0 to 3.3)
PrimaryPercentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination

Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting and diarrhea and were recorded by participants in the e-diary. Fever was defined as an oral temperature greater than or equal to (\>=) 38.0 degree Celsius (C) and classified as mild (38.0 to 38.4 degree C), moderate (38.5 to 38.9 degree C), severe (39.0 to 40.0 degree C) and grade 4 (\>40.0 degree C). Headache, nausea, fatigue, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily activity). Vomiting: mild (1-2 times in 24 hours \[H\]), moderate (\>2 times in 24 H), severe (required intravenous \[IV\] hydration). Diarrhea: mild (2-3 loose stools in 24 H), moderate (4-5 loose stools in 24 H), severe (\>=6 loose stools in 24 H). For all systemic events except fever, Grade 4= emergency room visit or hospitalization. Grade 4 events were classified by investigator or medically qualified designee.

Time frame:
From Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With Prespecified Systemic Events Within 7 Days After Vaccination
Percentage of participantsMaternal Participants: RSVpreFMaternal Participants: Placebo
Fever: >=38.0 degree C3.1 (1.0 to 7.0)1.8 (0.4 to 5.2)
Fever: 38.0 to 38.4 degree C1.8 (0.4 to 5.3)0.6 (0.0 to 3.3)
Fever: 38.5 to 38.9 degree C1.2 (0.1 to 4.4)0.6 (0.0 to 3.3)
Fever: 39.0 to 40.0 degree C0 (0.0 to 2.2)0.6 (0.0 to 3.3)
Fever: >40.0 degree C0 (0.0 to 2.2)0 (0.0 to 2.2)
Fatigue: Any35.0 (27.7 to 42.8)41.6 (34.0 to 49.5)
Fatigue: Mild20.9 (14.9 to 27.9)26.5 (20.0 to 33.9)
Fatigue: Moderate13.5 (8.7 to 19.7)13.9 (9.0 to 20.1)
Fatigue: Severe0.6 (0.0 to 3.4)1.2 (0.1 to 4.3)
Headache: Any33.1 (26.0 to 40.9)31.9 (24.9 to 39.6)
Headache: Mild21.5 (15.4 to 28.6)22.3 (16.2 to 29.4)
Headache: Moderate11.7 (7.2 to 17.6)8.4 (4.7 to 13.7)
Headache: Severe0 (0.0 to 2.2)1.2 (0.1 to 4.3)
Nausea: Any20.2 (14.4 to 27.2)17.5 (12.0 to 24.1)
Nausea: Mild17.2 (11.7 to 23.9)13.9 (9.0 to 20.1)
Nausea: Moderate3.1 (1.0 to 7.0)3.6 (1.3 to 7.7)
Nausea: Severe0 (0.0 to 2.2)0 (0.0 to 2.2)
Muscle pain: Any25.2 (18.7 to 32.5)14.5 (9.5 to 20.7)
Muscle pain: Mild17.2 (11.7 to 23.9)6.6 (3.4 to 11.5)
Muscle pain: Moderate8.0 (4.3 to 13.3)7.2 (3.8 to 12.3)
Muscle pain: Severe0 (0.0 to 2.2)0.6 (0.0 to 3.3)
Joint pain: Any16.6 (11.2 to 23.2)13.3 (8.5 to 19.4)
Joint pain: Mild11.0 (6.7 to 16.9)7.8 (4.2 to 13.0)
Joint pain: Moderate5.5 (2.6 to 10.2)5.4 (2.5 to 10.0)
Joint pain: Severe0 (0.0 to 2.2)0 (0.0 to 2.2)
Vomiting: Any12.9 (8.2 to 19.0)13.3 (8.5 to 19.4)
Vomiting: Mild9.8 (5.7 to 15.5)10.2 (6.1 to 15.9)
Vomiting: Moderate3.1 (1.0 to 7.0)3.0 (1.0 to 6.9)
Vomiting: Severe0 (0.0 to 2.2)0 (0.0 to 2.2)
Diarrhea: Any9.8 (5.7 to 15.5)9.6 (5.6 to 15.2)
Diarrhea: Mild6.1 (3.0 to 11.0)7.8 (4.2 to 13.0)
Diarrhea: Moderate3.1 (1.0 to 7.0)1.8 (0.4 to 5.2)
Diarrhea: Severe0.6 (0.0 to 3.4)0 (0.0 to 2.2)
PrimaryPercentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were included in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination
Percentage of participantsMaternal Participants: RSVpreFMaternal Participants: Placebo
Percentage of Maternal Participants With Adverse Events (AEs) From the Time of Vaccination Through 1 Month After Vaccination14.5 (9.6 to 20.7)24.1 (17.9 to 31.3)
PrimaryPercentage of Maternal Participants With Adverse Event of Special Interest (AESIs)

AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with pregnant maternal participants prior to/during delivery and post delivery. For maternal participants, the following were considered as protocol defined AESIs: diagnosis of Guillain-Barré syndrome; diagnosis of acute polyneuropathy without an underlying etiology; hypertensive disorders of pregnancy; preterm delivery (delivery at \<37 0/7 weeks' gestation) and atrial fibrillation. AESIs was to be recorded as an AE or serious adverse event (SAE) on the case report form (CRF).

Time frame:
From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)
Percentage of participantsMaternal Participants: RSVpreFMaternal Participants: Placebo
Percentage of Maternal Participants With Adverse Event of Special Interest (AESIs)14.0 (9.1 to 20.0)13.5 (8.8 to 19.6)
PrimaryPercentage of Maternal Participants With SAEs From Vaccination Throughout the Study

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.

Time frame:
From vaccination on Day 1 up to 6 months after delivery (up to maximum of 10 months)
Reported as:
Number · Percentage of participants
Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study
Percentage of participantsMaternal Participants: RSVpreFMaternal Participants: Placebo
Percentage of Maternal Participants With SAEs From Vaccination Throughout the Study34.9 (27.8 to 42.5)33.5 (26.5 to 41.2)
PrimaryPercentage of Infant Participants With AESIs From Birth Through 6 Months of Age

AESIs are a subset of targeted medical events based on review of known pharmacology, toxicology findings, possible class effects, published literature, and signals arising from safety data assessments, and on population under study. AESIs were based on targeted medical events associated with infants at birth. For infant participants the following were considered as protocol defined AESIs: preterm birth (born at \<37 0/7 week's gestation); birth weight 1001-2500 grams (g); developmental delay. Extremely preterm birth (born at \<28 0/7 week's gestation) and extremely low birth weight (less than or equal to \[\<=\] 1000 g) were reported as serious AESIs.

Time frame:
From birth up to 6 months of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age
Percentage of participantsInfant Participants: RSVpreFInfant Participants: Placebo
Percentage of Infant Participants With AESIs From Birth Through 6 Months of Age16.4 (11.2 to 22.8)17.5 (12.0 to 24.1)
PrimaryNumber of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age

Neonatal death was defined as the death of a live-born infant that occurred within a month after birth.

Time frame:
Within 1 Month after birth
Reported as:
Count of participants · Participants
Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Number of Infant Participants With Reported Neonatal Deaths From Birth Through 1 Months of Age13
PrimaryNumber of Infant Participants With Congenital Malformations/Anomalies at Birth

Congenital malformations/anomalies were defined as structural or functional anomalies that occurred during intrauterine life and could be identified prenatally, at birth or later in life.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Infant Participants With Congenital Malformations/Anomalies at Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Number of Infant Participants With Congenital Malformations/Anomalies at Birth47
PrimaryNumber of Infant Participants With Other Neonatal Problems at Birth

Other neonatal problem included dysmaturity, neonatal illness, hospitalization, and drug therapies.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Infant Participants With Other Neonatal Problems at Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Number of Infant Participants With Other Neonatal Problems at Birth2220
PrimaryNumber of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth

APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

Time frame:
1 minute after birth
Reported as:
Count of participants · Participants
Number of Infant Participants According to Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute After Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Score <402
Score 4 to <7910
Score 7 to 10158147
PrimaryNumber of Infant Participants According to APGAR Score at 5 Minutes After Birth

APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

Time frame:
5 minutes after birth
Reported as:
Count of participants · Participants
Number of Infant Participants According to APGAR Score at 5 Minutes After Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Score <400
Score 4 to <700
Score 7 to 10165158
PrimaryNumber of Infant Participants According to APGAR Score at 10 Minutes After Birth

APGAR was a fast evaluation technique used to evaluate a newborn baby's overall health. APGAR stands for (A) Appearance (skin coloration), (P) Pulse (heart rate), (G) Grimace (reflex response), (A) Activity (muscle tone) and (R) Respiration (breathing). Each component was given a score of 0, 1, or 2; after summing up scores for each component a total possible score was of 0 (worst condition) to 10 (best condition), where higher scores indicate better health. A score of 7 to 10 was good, 4 to \<7 was moderate, and \<4 was poor.

Time frame:
10 minutes after birth
Reported as:
Count of participants · Participants
Number of Infant Participants According to APGAR Score at 10 Minutes After Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
Score <400
Score 4 to <700
Score 7 to 106964
PrimaryNumber of Infant Participants According to Gestational Age (GA) at Birth

GA at birth was collected as:\>=24 to \<28 weeks, \>=28 to \<34 weeks, \>=34 to \<37 weeks, \>=37 to \<42 weeks, and \>=42 weeks.

Time frame:
At birth
Reported as:
Count of participants · Participants
Number of Infant Participants According to Gestational Age (GA) at Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
>=24 weeks to <28 weeks01
>=28 weeks to <34 weeks12
>=34 weeks to <37 weeks1410
>=37 weeks to <42 weeks155147
>=42 weeks16
PrimaryNumber of Infant Participants Requiring Hospitalization at Birth

Length of hospitalization at birth refers to the amount of time the infant remains admitted to the healthcare facility immediately following delivery and if that length of time is greater than or less than 72 hours. Postnatal standard of care procedures in South Africa were as follows: healthy newborns and their mothers were typically discharged within 24 hours after an uncomplicated vaginal delivery, or within 72 hours following an uncomplicated Caesarean section. These practices were supported by the Guidelines for Maternity Care in South Africa.

Time frame:
From birth until discharge from hospitalization (up to a maximum of 72 hours)
Reported as:
Count of participants · Participants
Number of Infant Participants Requiring Hospitalization at Birth
ParticipantsInfant Participants: RSVpreFInfant Participants: Placebo
<=72 hours136130
> 72 hours3333
Not reported23
PrimaryPercentage of Infant Participants With AEs From Birth to 1 Month of Age

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From birth to 1 month of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants With AEs From Birth to 1 Month of Age
Percentage of participantsInfant Participants: RSVpreFInfant Participants: Placebo
Percentage of Infant Participants With AEs From Birth to 1 Month of Age34.5 (27.4 to 42.1)44.0 (36.3 to 51.9)
PrimaryPercentage of Infant Participants With SAEs From Birth Through 6 Months of Age

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in congenital anomaly/birth defect or that was considered an important medical event.

Time frame:
From birth to 6 months of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age
Percentage of participantsInfant Participants: RSVpreFInfant Participants: Placebo
Percentage of Infant Participants With SAEs From Birth Through 6 Months of Age18.7 (13.2 to 25.4)21.7 (15.7 to 28.7)
PrimaryPercentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects. NDCMCs were reported as both AEs and SAEs.

Time frame:
From birth to 6 months of age
Reported as:
Number · Percentage of participants
Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age
Percentage of participantsInfant Participants: RSVpreFInfant Participants: Placebo
Percentage of Infant Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Birth Through 6 Months of Age1.2 (0.1 to 4.2)0.6 (0.0 to 3.3)
SecondaryGeometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants

GMTs and the corresponding 2-sided 95% confidence intervals (CIs) were calculated by exponentiating the mean logarithm of the neutralizing titers and the corresponding CIs based on the Student t distribution.

Time frame:
Before vaccination on Day 1 and at delivery
Reported as:
Geometric mean · Titer
Geometric Mean Titer (GMT) of Neutralizing Titer (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) and Respiratory Syncytial Virus Subgroup B (RSV B) Before Vaccination and at Delivery: Maternal Participants
TiterMaternal Participants: RSVpreFMaternal Participants: Placebo
RSV A: Before vaccination1649 (1443.5 to 1884.8)1662 (1462.8 to 1889.4)
RSV A: At delivery13192 (11347.9 to 15336.8)1663 (1439.6 to 1920.8)
RSV B: Before vaccination2242 (1937.9 to 2593.9)2075 (1795.8 to 2397.1)
RSV B: At delivery16424 (13999.2 to 19269.1)2297 (1996.1 to 2643.5)
SecondaryGeometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants

GMFRs and the corresponding 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs based on the Student t distribution. The GMFR for each vaccine group was defined as the geometric mean of the fold rises in the assay results from the specified time points.

Time frame:
Before vaccination on Day 1 to delivery
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of NTs for RSV A and RSV B From Before Vaccination to Delivery: Maternal Participants
Fold riseMaternal Participants: RSVpreFMaternal Participants: Placebo
RSV A8.0 (6.83 to 9.36)1.0 (0.89 to 1.12)
RSV B7.3 (6.20 to 8.66)1.1 (0.99 to 1.24)

Adverse events

Collected over Maternal participants: Local reactions and systemic events: From Day 1 to Day 7 after vaccination; SAEs and AESIs: From vaccination on Day 1 up to 6 months after delivery (maximum up to 10 months); Other AEs: From vaccination on Day 1 up to 1 month after vaccination; Infant participants: SAEs, AESIs and NDCMCs: From birth up to 6 months of age; Other AEs: From birth up to 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maternal Participants: RSVpreF1/172 (0.6%)60/172 (34.9%)103/172 (59.9%)
Maternal Participants: Placebo2/170 (1.2%)57/170 (33.5%)115/170 (67.6%)
Infant Participants: RSVpreF1/171 (0.6%)32/171 (18.7%)53/171 (31%)
Infant Participants: Placebo3/166 (1.8%)36/166 (21.7%)52/166 (31.3%)
Most frequent serious events
Showing 10 of 120
Most frequent serious events
EventMaternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: Placebo
Foetal distress syndromePregnancy, puerperium and perinatal conditions25/17222/1700/1710/166
Pre-eclampsiaPregnancy, puerperium and perinatal conditions4/1728/1700/1710/166
Gestational hypertensionPregnancy, puerperium and perinatal conditions6/1724/1700/1710/166
Jaundice neonatalPregnancy, puerperium and perinatal conditions0/1720/1704/1715/166
Low birth weight babyPregnancy, puerperium and perinatal conditions0/1720/1702/1715/166
Premature babyPregnancy, puerperium and perinatal conditions0/1720/1703/1715/166
Cephalo-pelvic disproportionPregnancy, puerperium and perinatal conditions2/1725/1700/1710/166
Prolonged labourPregnancy, puerperium and perinatal conditions5/1720/1700/1710/166
Transient tachypnoea of the newbornRespiratory, thoracic and mediastinal disorders0/1720/1700/1714/166
Prolonged pregnancyPregnancy, puerperium and perinatal conditions1/1724/1700/1710/166
Most frequent other events
Showing 10 of 104
Most frequent other events
EventMaternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: Placebo
Fatigue (FATIGUE)General disorders57/16369/1660/1710/166
Headache (HEADACHE)Nervous system disorders54/16353/1660/1710/166
Injection site pain (PAIN AT INJECTION SITE)General disorders44/16329/1660/1710/166
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders41/16324/1660/1710/166
Nausea (NAUSEA)Gastrointestinal disorders33/16329/1660/1710/166
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders27/16322/1660/1710/166
Vomiting (VOMITING)Gastrointestinal disorders21/16322/1660/1710/166
Low birth weight babyPregnancy, puerperium and perinatal conditions0/1720/17021/17116/166
Diarrhoea (DIARRHEA)Gastrointestinal disorders16/16316/1660/1710/166
Premature babyPregnancy, puerperium and perinatal conditions0/1720/17012/1718/166

Baseline characteristics

Maternal safety population included all randomized maternal participants who received at least 1 dose of the study intervention. Infant safety population included all infant participants who were born to vaccinated maternal participants.

Age, Customized
Age, Customized(Participants)Maternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: PlaceboTotal
<16 years00171166337
Between 16 and 44 years17217000342
Sex: Female, Male
Sex: Female, Male(Participants)Maternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: PlaceboTotal
Female1721708075497
Male009191182
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Maternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: PlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino145149168162624
Unknown or Not Reported27213455
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Maternal Participants: RSVpreFMaternal Participants: PlaceboInfant Participants: RSVpreFInfant Participants: PlaceboTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American171169170166676
White00000
More than one race00000
Unknown or Not Reported11103
08

Study locations

14 sites
  • Synergy Biomed Research Institute
    East London, Eastern Cape 5241, South Africa
  • Josha Research
    Bloemfontein, Free State 9301, South Africa
  • Worthwhile Clinical Trials
    Benoni, Gauteng 1500, South Africa
  • REIMED Reiger Park
    Boksburg, Gauteng 1459, South Africa
  • Wits RHI
    Johannesburg, Gauteng 2001, South Africa
  • University of Witwatersrand (WITS) - Vaccines and Infectious Diseases Analytics (VIDA)
    Johannesburg, Gauteng 2013, South Africa
  • Wits VIDA Nkanyezi Research Unit
    Johannesburg, Gauteng 2093, South Africa
  • Setshaba Research Centre
    Pretoria, Gauteng 0152, South Africa
  • Botho Ke Bontle Health Services
    Pretoria, Gauteng 0184, South Africa
  • Qhakaza Mbokodo Research Clinic
    Ladysmith, KwaZulu-Natal 3370, South Africa
  • Gole Biomed Research Centre
    Polokwane, Limpopo 0699, South Africa
  • MRC Unit on Child And Adolescent Health
    Cape Town, Western Cape 7700, South Africa
  • Gugulethu Green Clinic
    Cape Town, Western Cape 7750, South Africa
  • FAMCRU - Worcester
    Worcester, Western Cape 6850, South Africa
09

References and documents

Publications

  • Myer L, Wasserman E, Tabasum S, Shittu E, Liu Y, Jose L, Horne E, Moraba RS, Wilhase A, Zar HJ, Hussen N, Mogashoa MS, Malahleha M, Madhi SA, Sarwar UN, Snaggs H, Erdem R, Radley D, Kalinina EV, Pahud BA, Maddalena Lino M, Anastasiou OE, Swanson KA, Anderson AS, Gurtman A, Munjal I. Safety, Tolerability, and Immunogenicity of RSVpreF Vaccine in Pregnant Individuals Living with HIV. Vaccines (Basel). 2025 Dec 1;13(12):1218. doi: 10.3390/vaccines13121218. PubMed 41441684 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jun 2025, 14 months.

Results were first posted in Jul 2026, 1 year after primary completion.

Of 41 phase 3 interventional studies under Respiratory Tract Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 73. This study's 14 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2024
First posted
Mar 22, 2024
StartActual
Mar 12, 2024
Primary completionActual
Jun 11, 2025
CompletionActual
Jun 11, 2025
Results first posted
Jul 2, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06325657
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Mar 12, 2024
Primary completion
Jun 11, 2025
Completion
Jun 11, 2025
Results posted
Jul 2, 2026
Last update
Jul 2, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion